GlassScriptPhysician profile
Nickolai Talanin
NPI 1578682894
$9,374.40
in general payments reported to CMS, 2019-2025
34 companies · $2,509 in 2025
The $2,509 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $189 · 2021: $1,019 · 2022: $779 · 2023: $1,779 · 2024: $1,922 · 2025: $2,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,096 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,095.71 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.63 | 2019-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $889.19 | 2019-2025 | Aklief, Nemluvio |
| Janssen Biotech, INC. | $808.28 | 2019-2025 | Tremfya, Stelara, Simponi |
| Arcutis Biotherapeutics, INC. | $572.18 | 2023-2025 | Zoryve |
| Ucb, INC. | $526.00 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $523.88 | 2019-2025 | |
| Leo Pharma INC. | $508.41 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $508.28 | 2019-2025 | Dupixent |
| Amgen INC. | $460.73 | 2021-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $417.27 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $397.40 | 2023-2024 | Vtama |
| Pfizer INC. | $375.49 | 2019-2024 | |
| Genzyme Corporation | $354.48 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $328.58 | 2021-2023 | Winlevi, Absorica Ld, Ilumya |
| Botanix Sb INC | $268.63 | 2025 | Sofdra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $174.85 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $151.55 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $145.30 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $118.83 | 2021 | |
| Sandoz INC. | $104.55 | 2019-2021 | |
| Allergan, INC. | $97.33 | 2019 | |
| Janssen Scientific Affairs, LLC | $83.04 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.60 | 2019-2025 | Jublia, Duobrii, Arazlo |
| Paratek Pharmaceuticals, INC. | $71.24 | 2021-2025 | Nuzyra |
| Epi Health, LLC | $63.16 | 2019-2021 | |
| Organon LLC | $47.83 | 2025 | Vtama |
| Almirall LLC | $32.87 | 2021-2022 | |
| Biocon Biologics INC | $22.47 | 2025 | Yesintek |
| Verrica Pharmaceuticals INC. | $21.83 | 2023 | Ycanth |
| Biofrontera INC. | $18.17 | 2021 | |
| Novum Pharma, LLC | $15.99 | 2019 | |
| Mission Pharmacal Company | $13.50 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $13.47 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickolai Talanin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.